Corrigendum to ‘Clinical Practice Recommendations for Hematopoietic Cell Transplantation.’ Transplant Cell Ther. 2024 Sep;30(9):832-843
Transplant Cell Ther. 2025 Jun 21:S2666-6367(25)01206-0. doi:…
RETRACTED: Cejuela et al. Metformin and Breast Cancer: Where Are We Now? Int. J. Mol. Sci. 2022, 23, 2705
Int J Mol Sci. 2025 Jun 5;26(11):5407. doi: 10.3390/ijms26115407.ABSTRACTThe…
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial
Blood. 2025 Jun 11:blood.2025028313. doi: 10.1182/blood.2025028313.…
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma
Blood Adv. 2025 Jun 5:bloodadvances.2024015274. doi: 10.1182/bloodadvances.2024015274.…
Autocrine TGF-β signaling promotes cell motility and chemokine secretion in an angiomyolipoma-derived cell model of lymphangioleiomyomatosis
Am J Pathol. 2025 May 30:S0002-9440(25)00182-8. doi: 10.1016/j.ajpath.2025.04.019.…
Setting up a CAR-T Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation
Transplant Cell Ther. 2025 May 23:S2666-6367(25)01196-0. doi:…
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment
Blood. 2025 May 22:blood.2025029234. doi: 10.1182/blood.2025029234.…
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
Ann Oncol. 2025 May 16:S0923-7534(25)00200-5. doi: 10.1016/j.annonc.2025.05.008.…
Direct Ink Writing of 3D-Structured All-Carbon Electrodes with High Electrical Conductivity for (Vanadium) Redox Flow Batteries
Adv Sci (Weinh). 2025 May 15:e2417641. doi: 10.1002/advs.202417641.…
Transvaginal ultrasound assessment of corpus callosal length in the fetus: multicenter cross-sectional study
Ultrasound Obstet Gynecol. 2025 May 5. doi: 10.1002/uog.29227.…
Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group
Bone Marrow Transplant. 2025 Apr 15. doi: 10.1038/s41409-025-02568-4.…
Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study
Cancers (Basel). 2025 Mar 28;17(7):1137. doi: 10.3390/cancers17071137.ABSTRACTBACKGROUND/OBJECTIVES:…
